Does ALLR pay a dividend and is it safe?

Allarity Therapeutics Inc. (ALLR) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ALLR / dividends

OPTH (46) DARE (36) CTXR (40) NCEL (28) ⌘ Pro Terminal →

Allarity Therapeutics Inc. (ALLR) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.98 +12.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.00

Allarity Therapeutics Inc. (ALLR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $13.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALLR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Allarity Therapeutics Inc. (NASDAQ: ALLR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.98 (+12.33% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ALLR ranks #737 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALLR compare to OPTH and DARE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALLR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OPTH (Optimi Health Corp.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $13.8M) and DARE (Dare Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, ALLR leads on earnings multiple (N/A) while ALLR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALLR?

▼

Per ALLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860657), Allarity Therapeutics Inc. generated $35.3M in revenue (-53.7% YoY), -$11.2M in net income, and -$14.8M in free cash flow against $18.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.00 (+2.03%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALLR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY ALLR SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (28% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.87+1.1% Next Q

Q2 (-2Q)

Grade E$0.88+4.5% Next Q

Q3 (-1Q)

Grade E$0.92+6.5% Next Q

Current

Grade E$0.98-9.2% Hist 90D α

Trajectory: E (24) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALLR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALLR currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.07) and Max Pain ($1.03) forces dealer call-delta covering toward $1.93.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALLR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALLR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALLR)

✓Walkthrough of ALLR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALLR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.60%▼ DESCENDING CHANNEL

2026-11-03O $0.89H $0.98L $0.87C $0.98VOL 179.5K

RES: $1.27SUP: $0.76SMA50: $1.07SMA200: $1.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALLR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALLR Butterfly Map → + Track ALLR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -53.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALLR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALLR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALLR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALLR)

Health Care Rank #737 of 1015 ⚔️ OPTH vs ALLR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALLR vs. OPTH, DARE, CTXR, NCEL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Allarity Therapeutics Inc. (ALLR) ranks #737 by composite RQD confidence (32/100, grade E) and #859 by equity capitalization ($13.8M). Within this direct 5-issuer industry benchmark cohort, ALLR leads on earnings valuation at N/A trailing P/E, while ALLR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ALLR at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALLR ACTIVE Allarity Therapeutics Inc.	E	32/100	—	—	-35.0%	+12.33%	$13.8M	Benchmark Subject
OPTH Optimi Health Corp.	D	46/100	—	—	—	-7.05%	$13.8M	/opth-vs-allr →
DARE Dare Bioscience Inc.	D-	36/100	—	71.3%	-35.0%	-6.37%	$13.8M	/dare-vs-allr →
CTXR Citius Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+7.44%	$14.4M	/ctxr-vs-allr →
NCEL NewcelX Ltd.	E	28/100	—	—	-35.0%	-2.35%	$14.7M	/ncel-vs-allr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860657 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allarity Therapeutics Inc. (ALLR) reported GAAP revenue of $35.3M (-53.7% vs. FY2024 revenue of $76.3M , and -26.4% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+16.0% YoY). On the balance sheet, ALLR closed FY2025 with $18.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.3M	-$11.2M	-$14.8M	-$14.8M	$18.3M	—
FY2024 (FY)	2024-12-31	$76.3M	-$24.5M	-$17.4M	-$17.6M	$22.6M	—
FY2023 (FY)	2023-12-31	$48.0M	-$11.9M	-$12.7M	-$12.7M	—	—

3. ALLR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALLR compare to OPTH and DARE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALLR?

Where is ALLR trading relative to its 50-day, 200-day, and 52-week technical levels?

ALLR last traded at $0.98 (+12.33% on volume of 166,854 shares), positioning the stock -8.41% below its 50-day simple moving average ($1.07) and -19.01% below its 200-day simple moving average ($1.21). Across its 52-week range of $0.77 to $1.84, ALLR sits at the 19.6% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

Direct Sub-Reports: ALLR RQD Cockpit ALLR 12M Forecast ALLR Earnings & Move ALLR Dividends & DRIP ALLR Insiders & 13F ALLR Whale Options ALLR Profit Sankey ALLR News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

ALLR — Allarity Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Allarity Therapeutics Inc. (ALLR) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.98 (+12.33% 1D, market capitalization $13.8M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. — for specific product lines, customer base, or revenue model. The FY 2025 and FY 2024 financials report revenue of — in each period, indicating no reported revenue in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Allarity Therapeutics Inc. (ALLR) reported $35.3M in annual revenue (up from $76.3M in FY2024, -53.7% YoY) and -$11.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($48.0M revenue, -$11.9M net income) through FY2025, ALLR scaled operating cash flow to -$14.8M and free cash flow to -$14.8M, backed by $18.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.77 – $1.84 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the only sector context provided is the Health Care classification and a beta of 1.0.

Key Question #1: Can ALLR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $35.3M and free cash flow of -$14.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ALLR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ALLR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Allarity Therapeutics Inc. (ALLR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALLR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now

Yahoo Finance report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Allarity Therapeutics Ends $6 Million Stock Purchase Agreement With Tumim

TradingView report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Applicable resale coverage survives as Allarity Therapeutics (ALLR) ends its Tumim stock sale agreement.

Stock Titan report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

The Manila Times report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

ALLR Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.21 Per Share - Pre-Announcement Alert

https://www.dars.gov.et/ report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TipRanks • 1d ago

Allarity Therapeutics Ends Stock Purchase Agreement, Shifts Financing

TipRanks report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment

On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALLR Bull vs. Bear Conversation Board — What's Your Call at $0.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALLR 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $1.10 (+26.4%)

📌 Pinned Debate

The stock trades at $0.89, near the low of its $0.77 - $1.84 52-week range, with a first commercial CLIA laboratory services agreement

The stock trades at $0.89, near the low of its $0.77 - $1.84 52-week range, with a first commercial CLIA laboratory services agreement reported in the news wire.. When you look under the hood at ALLR, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $1.84. My 12M target is $1.10.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $0.87 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.66 (-24.1%)

Spot @ $0.87

The company reports $0.0M revenue, ROIC of -35%, and a Piotroski F-Score of 2/9 while cash declined from $19.5M to $14.7M.

Fading this rally in ALLR at $0.87. The company reports $0.0M revenue, ROIC of -35%, and a Piotroski F-Score of 2/9 while cash declined from $19.5M to $14.7M.. With a beta of 1.0 and the stock sitting at $0.87 (52-wk range $0.77–$1.84), the easy multiple expansion is already priced in.